Pilot study suggests injectable BOAS therapy may widen options: full analysis
Version 2 — Full analysis
A new pilot study suggests an injectable therapy may eventually expand the treatment toolkit for dogs with brachycephalic obstructive airway syndrome. In The Veterinary Journal, investigators reported that all six British bulldogs enrolled in an early Snoretox-1 study improved by at least one BOAS grade, with effects lasting from 20 to 53 weeks after treatment. The investigational product was developed by Snoretox and RMIT University, and is being positioned as a potential alternative or complement to surgery for selected brachycephalic dogs. (sciencedirect.com)
That matters because BOAS is still primarily managed as an anatomic and surgical disease, even though clinicians increasingly recognize it as a broader, lifelong welfare issue. Common signs include stertor, exercise and heat intolerance, sleep disruption, regurgitation, and, in severe cases, collapse or cyanosis. Standard treatment often involves combinations of rhinoplasty, partial staphylectomy, sacculectomy, tonsillectomy, or turbinectomy, but prognosis is variable because obstruction can occur at multiple airway levels, and brachycephalic patients also carry higher anesthetic risk. (dvm360.com)
According to RMIT’s April 23, 2026 announcement, the six affected bulldogs had severe enough disease that they struggled with a three-minute walk before treatment, then completed it more easily afterward with less breathing noise and effort. The university said the therapy works by improving muscle tone in the floor of the mouth to help support airway patency. RMIT also said the technology has been in development for more than 15 years, and that a larger trial is now being planned. (rmit.edu.au)
The published abstract and article summary add a few important details. The study evaluated bilateral geniohyoid injection of Snoretox-1 in six British bulldogs and used the Kennel Club/University of Cambridge Respiratory Function Grading framework as a key outcome measure. The authors reported clinically meaningful improvement in veterinarian-assessed BOAS grade, alongside owner-reported gains in health and wellbeing. They also noted that some dogs appeared to benefit despite prior surgery, an observation that, if confirmed, could be especially relevant in referral settings where residual signs after BOAS procedures are common. (sciencedirect.com)
Independent expert reaction specific to this paper appears limited so far, but the broader field has been moving toward more structured BOAS assessment and more cautious expectations around surgery. Recent clinical guidance in dvm360 emphasizes that not all components of BOAS can be corrected surgically and that a return to normal airway function is unrealistic in many brachycephalic dogs. That context makes the Snoretox-1 data interesting, but also underscores how preliminary they are: this was a six-dog pilot, not a controlled pivotal trial, and the available public materials do not establish where the therapy would fit relative to surgery, medical management, weight reduction, or multimodal care. (dvm360.com)
Why it matters: For general practitioners, surgeons, and brachycephalic-focused teams, the bigger takeaway is that BOAS innovation may be shifting beyond tissue resection alone. A therapy that improves neuromuscular support of the upper airway could be useful for dogs that are poor surgical candidates, pet parents reluctant to pursue surgery, or patients with incomplete response after standard procedures. But the enthusiasm should stay measured. Before practice adoption becomes realistic, clinicians will need more than proof-of-concept: they’ll need larger cohorts, clearer adverse-event reporting, durability data, repeat-dosing information, and evidence about which BOAS phenotypes are most likely to respond. (rmit.edu.au)
What to watch: Watch for enrollment details from the larger follow-up trial, peer-reviewed publication of full methods and safety outcomes, and any signal that Snoretox-1 is being studied as a standalone therapy versus an adjunct to conventional BOAS surgery. (rmit.edu.au)